Emily Blanton
Urogynecology and Reconstructive Pelvic Surgery · New York, NYNPI 1346530151
Payments from drug & device makers
Across 47 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$191
- Avion Pharmaceuticals$139
- Mayne Pharma Commercial LLC$94
- Aspira Women's Health Inc$76
- Therapeuticsmd, Inc.$64
- Collegium Pharmaceutical, Inc.$58
- plus $380 from 10 others
What the payments were for
- Food & beverage$96096%
- Education$424%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 8 | $191 |
| Avion Pharmaceuticals | 10 | $139 |
| Mayne Pharma Commercial LLC | 4 | $94 |
| Aspira Women's Health Inc | 1 | $76 |
| Therapeuticsmd, Inc. | 3 | $64 |
| Collegium Pharmaceutical, Inc. | 1 | $58 |
| Lupin Inc. | 3 | $57 |
| Coopersurgical, Inc. | 2 | $50 |
| Agile Therapeutics, Inc. | 3 | $45 |
| AMAG Pharmaceuticals, Inc. | 2 | $42 |
| Evofem Biosciences, Inc. | 2 | $40 |
| Myovant Sciences Inc. | 2 | $40 |
| Exeltis, USA Inc. | 2 | $38 |
| Millicent US Inc | 2 | $34 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Merck | 1 | $14 |
How this compares
$1,001 in reported general payments places this provider in the 15th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.
See all urogynecology and reconstructive pelvic surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MenostarEstradiol | 11 | $4,265 |
| YuvafemEstradiol | 13 | $1,866 |
| Estradiol | 14 | $1,525 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in New York
- Helai HeshamNew York$156K
- Melissa LaudanoNew York$81K
- Kimberly FerranteNew York$69K
- Larissa RodriguezNew York$43K
- Svjetlana LozoNew York$41K
- Alan GarelyNew York$12K
- Ido SirotaNew York$12K
- Christina EscobarNew York$12K
- Feven GetanehNew York$4K
- Chandhana PakaNew York$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.